Novartis stock slides as centerpiece of $12B Avidity buyout flunks ‘crucial’ phase 3 test — Live Feedhttps://www.live-feeds.com/feed/novartis-stock-slides-as-centerpiece-of-12b-avidity-buyout-flunks-crucial-phase-3-testContinuously updated, source-cited coverage. Novartis Plummets as Avidity Buyout Drug Flunks Phase 3 Testhttps://www.live-feeds.com/feed/novartis-stock-slides-as-centerpiece-of-12b-avidity-buyout-flunks-crucial-phase-3-testhttps://www.live-feeds.com/feed/novartis-stock-slides-as-centerpiece-of-12b-avidity-buyout-flunks-crucial-phase-3-test#u62683Wed, 09 Sep 2026 11:10:17 +0000Novartis shares plummeted 10 percent, heading for their worst day on record, after a crucial phase 3 clinical trial failure. The failed drug served as the centerpiece of a 12 billion dollar Avidity buyout. This setback represents the second pipeline failure for the pharmaceutical major within a single week, adding to a total of three recent drug trial setbacks. Meanwhile, Dyne Therapeutics shares fell 31 percent in premarket trading. The trial failure serves as a cautionary tale for pharmaceutical mergers and acquisitions across the industry.Why it mattersPharmaceutical companies frequently re